Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA phase III maintenance immunotherapy in metastatic colorectal cancer
2014-000834-50Phase 3Terminated
- Sponsor
- Mologen AG
- Start
- May 2014
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of lefitolimod in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 arms), sponsored by Mologen AG. Primary endpoint: Overall survival after randomization (OS). Started May 2014; status: terminated.
02
Drugs
lefitolimod
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2014-000834-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000834-50.